AIM ImmunoTech Inc.

Contributing Author

Recent Articles by AIM ImmunoTech Inc.

11 hours	AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million AIM GlobeNewswire
Mar-02	AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer AIM -14.89% GlobeNewswire
Feb-27	AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering AIM -8.32% GlobeNewswire
Feb-25	AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 AIM GlobeNewswire
Feb-23	AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer AIM GlobeNewswire
Feb-12	CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering AIM +58.23% AIM -6.36% GlobeNewswire
Feb-12	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event AIM -6.36% GlobeNewswire
Feb-11	AIM ImmunoTech Announces Commencement of Rights Offering AIM -13.51% GlobeNewswire
Feb-06	AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial AIM -7.32% GlobeNewswire
Feb-05	AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer AIM +16.59% GlobeNewswire
Jan-27	AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering AIM GlobeNewswire
Jan-23	AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering AIM -5.16% GlobeNewswire
Dec-30	AIM ImmunoTech Announces Stock Dividend AIM -10.32% AIM GlobeNewswire
Dec-10	AIM ImmunoTech Announces Release of the Next CEO Corner Segment AIM GlobeNewswire
Dec-01	AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series AIM GlobeNewswire
Nov-18	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program AIM -7.64% GlobeNewswire
Nov-10	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer AIM -6.37% GlobeNewswire
Nov-04	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting AIM -20.40% GlobeNewswire
Nov-03	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue AIM GlobeNewswire
Oct-20	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit AIM GlobeNewswire
Sep-25	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors AIM GlobeNewswire
Sep-22	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth AIM +6.16% GlobeNewswire
Sep-04	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland AIM GlobeNewswire
Aug-21	AIM ImmunoTech Announces Release of the Next CEO Corner Segment AIM +8.47% GlobeNewswire
Aug-15	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update AIM GlobeNewswire
Aug-14	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AIM GlobeNewswire
Aug-06	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) AIM GlobeNewswire
Aug-04	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval AIM +6.36% GlobeNewswire
Jul-31	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering AIM GlobeNewswire
Jul-29	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering AIM -56.25% GlobeNewswire
Jul-28	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer AIM -14.29% GlobeNewswire
Jul-02	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies AIM GlobeNewswire
Jun-20	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements AIM +10.96% GlobeNewswire
Jun-17	AIM ImmunoTech Resumes Trading on NYSE American AIM +6.84% GlobeNewswire

AIM ImmunoTech Inc.

Recent Articles by AIM ImmunoTech Inc.

Upgrade your FINVIZ experience